Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07107087

A Multimodal Integrated Intervention for Kidney Cachexia

A Multimodal Integrated Intervention for Kidney Cachexia — Recruiting • Non-phase study • Oncology • NCT07107087.

📅 26 Aug 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07107087
Start
2026-09
Completion
2027-08-01
ClinicaliQ Trial Snapshot
  • A Multimodal Integrated Intervention for Kidney Cachexia — Recruiting • Non-phase study • Oncology • NCT07107087.
  • Combined exercise, dietary advice, and anti-inflammatory supplements may help prevent severe muscle wasting in haemodialysis patients.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This lay description has been written in conjunction with, and the content approved by our Patient and Public Involvement collaborators. Patients with kidney cachexia will experience extreme muscle loss, reduced strength and symptoms including fatigue, reduced appetite and lower quality of life. Patients are also at an increased risk of hospitalisation and shortened life expectancy. Previous research suggests that treatments that target several causes of the muscle wasting syndrome (known as cachexia), show better outcomes for patients than treatments using just one method (for example only exercise). The investigators want…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Wellbeing support demand for cancer patients grows
Oncology · BBC Health · 25 Oct 2026
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision may not meet patient…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Very hot drinks may damage the food pipe and increase cancer risk
Oncology · BBC Health · 09 Sep 2026
The International Agency for Research on Cancer (IARC) has classified drinking "very hot" beverages (>65°C) as a probable carcinogen (Group 2A), associated…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment
Oncology · 20 Oct 2026
Trastuzumab deruxtecan is recommended as an option for HER2-positive unresectable or metastatic breast cancer only after 1 or more prior lines of…
View guideline →
Clinical Brief
Very hot drinks may damage the food pipe and increase cancer risk
Oncology · BBC Health · 08 Sep 2026
The International Agency for Research on Cancer has classified drinking "very hot" beverages (above 65°C) as probably carcinogenic, with repeated thermal injury…
View brief →
Clinical Brief
Haematology centre for cancer patients at risk over ‘disgraceful’ funds move
Oncology · BBC Health · 22 Oct 2026
The Department of Health is withdrawing £1.5m funding from a haematology centre serving cancer patients in Belfast, creating significant financial jeopardy for…
View brief →